Skip to main content

Table 2 Lymphocyte frequencies (mean %) after ovx in WT and Ncf1-deficient mice (n = 6–9 mice per group, t-test comparing ovx vs. sham for each genotype)

From: Ncf1 affects osteoclast formation but is not critical for postmenopausal bone loss

Leukocyte population Sub population WT Sham (%, ±SD) WT ovx (%, ±SD) p-value Ncf1*/* Sham (%, ±SD) Ncf1*/* ovx (%, ±SD) p-value
4 weeks after ovx       
DCs (CD11c+)   2.5 ± 0.9 2.4 ± 0.2 n.s. 2.3 ± 0.7 2.6 ± 0.5 n.s.
  MHC II+ 44 ± 10 44 ± 9.2 n.s. 49 ± 16 51 ± 16 n.s.
  CD80+ 19 ± 3.8 17 ± 4.3 n.s 18 ± 4.1 25 ± 8.4 0.04
T-cell (CD4+)   1.6 ± 0.3 0.8 ± 0.2 <0.0001 1.2 ± 0.3 0.93 ± 0.3 0.04
  CD69+ 22 ± 6 26 ± 5.5 n.s 24 ± 8.8 33 ± 8.0 n.s
T cell (CD8+)   1.4 ± 0.2 0.74 ± 0.2 <0.0001 0.94 ± 0.4 0.8 ± 0.3 n.s
  CD69+ 17 ± 7.4 23 ± 3.7 n.s 21 ± 7.7 25 ± 8.0 n.s
2 weeks after ovx        
DCs (CD11c+)   7.3 ± 0.9 6.6 ± 0.1 n.s. 6.6 ± 1.0 6.2 ± 1.1 n.s.
  MHC II+ 40 ± 6.0 38 ± 2.9 n.s. 37 ± 4.8 36 ± 4.4 n.s.
  CD80+ 30 ± 3.0 24 ± 3.2 0.001 31 ± 4.2 25 ± 4.6 0.03
T-cell (CD4+)   2.1 ± 0.5 0.7 ± 0.2 <0.0001 2.3 ± 0.6 1.1 ± 0.5 0.001
  CD69+ 21 ± 5.3 33 ± 8.4 0.002 19 ± 6.5 26 ± 3.2 0.02
T cell (CD8+)   2.2 ± 0.9 0.8 ± 0.2 <0.001 2.0 ± 1.3 0.56 ± 0.16 0.01
  CD69+ 9.8 ± 2.3 19 ± 5.0 <0.001 12 ± 3.7 25 ± 8.5 0.002